Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: This drug safety review provides an update on the long-term cardiovascular risks of therapeutic stimulant class medication for children and adults with attention-deficit/hyperactivity disorder (ADHD). AREAS COVERED: Relevant literature on the long-term (defined as ≥ 12 months) cardiovascular effects of stimulant class medications for ADHD was sought using PubMed searches for clinical literature, epidemiological reports, as well as reviews of post-marketing data and clinical guidelines/consensus statements. Comparison was made to the non-stimulant atomoxetine. EXPERT OPINION: Long-term cardiovascular risks of stimulants for healthy children and adults with ADHD are limited to minor mean elevations in blood pressure (≤ 7 mmHg) and heart rate (≤ 10 bpm). In a sizeable minority of individuals these elevations are greater and/or reach a clinical threshold. Subjective complaints may also be anticipated during long-term treatment, yet without an increase in serious cardiac outcomes above background rates per age. Future research is needed on possible latent or cumulative cardiovascular risks in healthy individuals, as well as the longer-term cardiovascular safety in vulnerable populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis
Simon, V., Czobor, P., Bálint, S., Mészáros, Á., & Bitter, I. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.048827 · Cited by 1,601
Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis
Faraone, S. V., & Buitelaar, J. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0054-3 · Cited by 485 · cited 3×
“Overall, the mean effect size of stimulants is large in adult and child ADHD populations [20,21].”
BackgroundADHD Drugs and Serious Cardiovascular Events in Children and Young Adults
Cooper, W. O., Habel, L. A., Sox, C. M., Chan, K. A., Arbogast, P. G., Cheetham, T. C., Murray, K. T., Quinn, V. P., Stein, C. M., Callahan, S. T., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1110212 · Cited by 411
ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
Habel, L. A., Cooper, W. O., Sox, C. M., Chan, K. A., Fireman, B. H., Arbogast, P. G., Cheetham, T. C., Quinn, V. P., Dublin, S., Boudreau, D. M., et al. (2011) · JAMA · doi:10.1001/jama.2011.1830 · Cited by 297 · cited 1×
“The largest study in adults (25 -- 64 years old) during this time period was a retrospective cohort study with ADHD medication users (n = 150,359) matched to two nonusers [53].”
BackgroundVetter, V. L., Elia, J., Erickson, C., Berger, S., Blum, N., Uzark, K., & Webb, C. L. (2008) · Circulation · doi:10.1161/circulationaha.107.189473 · Cited by 296 · cited 2×
“Findings are consistent with benign normal ECG variants found in similar rates in samples of healthy children with and without ADHD [41].”
BackgroundNutt, D. J., Fone, K., Asherson, P., Bramble, D., Hill, P., Matthews, K., Morris, K. A., Santosh, P., Sonuga-Barke, E., Taylor, E., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106073219 · Cited by 259 · cited 2×
“Of available agents, stimulant class medications are consistently recommended as first-line agents across the age range [4,16-18].”
BackgroundSpencer, T. J., Greenbaum, M., Ginsberg, L. D., & Murphy, W. R. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0152 · Cited by 257
Volkow, N. D., Wang, G.-J., Tomasi, D., Kollins, S. H., Wigal, T. L., Newcorn, J. H., Telang, F. W., Fowler, J. S., Logan, J., Wong, C. T., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4461-11.2012 · Cited by 237 · cited 1×
“1 Mechanism of action Improvement in ADHD symptomatology has been correlated with enhanced brain dopamine (DA) signaling by stimulant class medications in relevant brain regions; methylphenidate increases DA by blocking DA transporters (DATs) while amphetamine releases DA from the terminal using the DAT as carrier [13…”
BackgroundCatalá-López, F., Peiró, S., Ridao, M., Sanfélix-Gimeno, G., Gènova-Maleras, R., & Catalá, M. A. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-168 · Cited by 176
Cited by
Adult ADHD and Comorbid Somatic Disease: A Systematic Literature Review
Instanes, J. T., Klungsøyr, K., Halmøy, A., Fasmer, O. B., & Haavik, J. (2018) · Journal of Attention Disorders · doi:10.1177/1087054716669589 · Cited by 232
Reed, V. A., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., Coghill, D. R., Kryzhanovskaya, L. A., & Savill, N. C. (2016) · CNS Drugs · doi:10.1007/s40263-016-0349-0 · Cited by 113
Fu, D., Wu, D.-D., Guo, H.-L., Hu, Y.-H., Xia, Y., Ji, X., Fang, W.-R., Li, Y.-M., Xu, J., Chen, F., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.780921 · Cited by 66
Groenman, A. P., Schweren, L. J. S., Dietrich, A., & Hoekstra, P. J. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1301928 · Cited by 46
Metadata
- Authors
- Hammerness, P. G., Karampahtsis, C., Babalola, R., & Alexander, M. E.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa Healthcare
- Published
- 2015-02-03
- Volume
- 14
- Issue
- 4
- Pages
- 543-551
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2115322414
- Cited by
- 30
- References
- 18
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks? https://app.cochat.ai/papers/10.1517/14740338.2015.1011620
- The paper
- Hammerness, P. G., Karampahtsis, C., Babalola, R., & Alexander, M. E. (2015). Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks? Expert Opinion on Drug Safety. https://doi.org/10.1517/14740338.2015.1011620
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.